期刊
TRANSLATIONAL ONCOLOGY
卷 14, 期 2, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2020.100996
关键词
Phosphorylated signal transducer and activator of transcription-3 (pSTAT3); Primary cancer paired with liver metastasis; Colorectal cancer; Immunohistochemistry; Clinical decisions
类别
资金
- Ottawa Hospital Department of Medicine
The study found differences in phosphorylated STAT3 expression between liver metastases and primary tumors in patients with advanced colorectal cancer, but these differences did not affect survival outcomes. Discordant STAT3 expression suggests the potential need for confirmatory liver tumor biopsy in a biomarker-driven treatment approach.
Background: Signal Transducer and Activator of Transcription-3 (STAT3) mediates cellular functions. We assessed the IHC expression of phosphorylated STAT3 (pSTAT3) in paired primary tumors and liver metastases in patients with advanced stage colorectal cancer (CRC). Methods: We included patients with tissue blocks available from both the primary CRC and a surgically resected liver metastasis. The IHC pSTAT3 expression agreement was measured using Cohen's kappa statistic. Results: The study included 103 patients, 55% male, median age was 64. 43% tumors originated in rectum, and 63% of the primary tumors were synchronous. Expression of pSTAT3 was 76% in liver metastases and 71% in primary tumors. A difference in pSTAT3 staining between the primary tumor and liver metastases was noted in 64%. There was lost expression of pSTAT3 in the liver metastases in 28% and gained expression in 36% of cases compared to the primary. The kappa statistic comparing agreement between staining patterns of the primary tumors and liver metastases was a less-than-chance , at-0.02. Median survival was 4.9 years, with no difference in survival outcomes by pSTAT3 expression in the primary tumor or liver metastases. Discussion: STAT3 is not a prognostic marker in the selective setting of metastatic CRC to liver, but it may remain a potential therapeutic target given most liver metastases expressed pSTAT3. Discordant pSTAT3 expression in between primary tumors and paired liver metastases suggests that use of this class of drug to treat liver predominant metastatic colorectal cancer in a biomarker-driven approach may require confirmatory liver tumor biopsy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据